Detection of A-synuclein Aggregate as Biomarker in Diagnosing Parkinson's Disease at Early Stage by Using Protein Misfolding Cyclic Amplification (PMCA)
Key facts
- Who runs it
- Huashan Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Started
- 1 Oct 2024
- Ended
- 30 Dec 2025
- Type of study
- Observational, 4 groups
- Treatments tested
- Biomarker assay
- Record updated
- 19 March 2025
- Why it stopped
- Our applied project did not receive funding support, so it cannot proceed, leading to the withdrawal of the study.
Who can take part
- Age
- 50 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (48)Hide the full registry criteria
Who can take part
- Clinical diagnosis of "probable PD" by two neurologists specializing in movement disorders according to the International Parkinson and Movement Disorder Society (MDS) Clinical Diagnostic Criteria for PD (2015)
- Age 50-75, disease duration is less than 1 year, and Hoehn \& Yahr Stage I
- the dopamine reuptake transporter (DAT) is significantly reduced in striatum on PET imaging
- Metabolic brain network detected by fluorine-18-labelled-fluorodeoxyglucose-PET(18F-FDG PET) is consistent with Parkinson's disease-related pattern (PDRP), with FDG hypermetabolism being in basal ganglia and cerebellum
- Good response to anti-PD medications
- Ability of completing questionnaires
- Ability of providing informed consent
- Willingness of being assessed by neurologists during off-medication state defined as discontinuing anti-PD medications for at least 12 hours before assessment
- Clinical diagnosis of "probable MSA" by two neurologists specializing in movement disorders according to the International Parkinson and Movement Disorder Society (MDS) second consensus criteria for MSA (2019)
- Age 50-75, and disease duration is less than 1 year
- Metabolic brain network detected by fluorine-18-labelled-fluorodeoxyglucose-PET(18F-FDG PET) is consistent with MSA related pattern
- Ability of completing questionnaires
- Ability of providing informed consent
- Willingness of being assessed by neurologists during off-medication state defined as discontinuing anti-PD medications for at least 12 hours before assessment
- Clinical diagnosis of "probable PSP" by two neurologists specializing in movement disorders according to MDS Clinical Diagnostic Criteria for PSP (2017)
- Age 50-75, disease duration is less than 1 year
- Metabolic brain network detected by fluorine-18-labelled-fluorodeoxyglucose-PET(18F-FDG PET) is consistent with PSP related pattern
- Ability of completing questionnaires
- Ability of providing informed consent
- Willingness of being assessed by neurologists during off-medication state defined as discontinuing anti-PD medications for at least 12 hours before assessment
- Age 50-75
- No history of neurodegenerative disease of the central nervous system
- No history of infective disease of the central system
- Ability of completing questionnaires
- Ability of providing informed consent
Who cannot take part
- Secondary parkinsonism (ie. drug induced)
- Secondary parkinsonism (ie. drug induced)
- Secondary parkinsonism (ie. drug induced)
- History of being diagnosed as any cancer within 5 years
- Presence of any condition risking the procedure of performing lumbar puncture (LP)
- History of being diagnosed as any cancer within 5 years
- Presence of any condition risking the procedure of performing lumbar puncture (LP)
- History of being diagnosed as any cancer within 5 years
- Presence of any condition risking the procedure of performing lumbar puncture (LP)
- Inability to comply with study procedures; For controls without diagnosis of neurodegenerative disorders
- With prodromal symptoms of PD, such as rapid eye movement sleep behavior disorder (RBD)
- History of being diagnosed as any cancer within 5 years
- Presence of any condition increasing the risk of the procedure of performing lumbar puncture (LP)
- Atypical parkinsonisms like MSA or PSP etc
- Presence of any item in 10 red flags of the MDS Clinical Diagnostic Criteria for PD (2015) in the comprehensive assessments during follow-up
- Pregnancy
- Inability to comply with study procedures; For early MSA patients
- Pregnancy
- Inability to comply with study procedures; For PSP patients
- Pregnancy
- Pregnancy
- Inability to comply with study procedures
Other criteria
- For early PD patients
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The study will investigate the biomarker of a-synuclein aggregate in CSF detected by protein misfolding cyclic amplification (PMCA) and its sensitivity and specificity in diagnosing Parkinson's disease at H-Y stage I and disease duration less than 1 year, compared with that from age-matched controls without neurodegeneration, those with Multiple System Atrophy (MSA) as a disease control with a-synucleinopathy, and those with Progressive Supranuclear Palsy (PSP) as a control with non-a-synucleinopathy neurodegeneration.
The 4 groups in the trial
- Parkinson's Disease
Subjects who have a PD diagnosis
Treatment: Biomarker assay
- Multiple System Atrophy
Subjects who have an MSA diagnosis
Treatment: Biomarker assay
- Progressive Superanuclear Palsy
Subjects who have a PSP diagnosis
Treatment: Biomarker assay
- Age-matched controls
Subjects who do not have a diagnosed neurological disorder
Treatment: Biomarker assay
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 19 March 2025